Literature DB >> 17908968

Short telomeres: a novel potential predictor of relapse in Ewing sarcoma.

Smadar Avigad1, Inna Naumov, Anat Ohali, Marta Jeison, Gili Halevy Berco, Jacques Mardoukh, Batia Stark, Shifra Ash, Ian J Cohen, Isaac Meller, Yehuda Kollender, Josephine Issakov, Isaac Yaniv.   

Abstract

PURPOSE: Despite advances in therapy, >50% of patients with Ewing sarcoma will relapse. The current prognostic factors are not optimal for risk prediction. Studies have shown that telomere length could predict outcome in different malignancies. Our aim was to evaluate whether telomere length could be a better prognostic factor in Ewing sarcoma and correlate the results with clinical variables, outcome, and chromosomal instability. EXPERIMENTAL
DESIGN: Telomere length was determined in the primary tumor and peripheral blood of 32 patients with Ewing sarcoma. Chromosomal instability was evaluated by combining classical cytogenetics, comparative genomic hybridization and random aneuploidy. Telomere length was correlated to clinical variables, chromosomal instability, and outcome.
RESULTS: In 75% of the tumors, changes in telomere length, when compared with the corresponding peripheral blood lymphocytes, were noted. The majority of changes consisted of a reduction in telomere length. Patients harboring shorter telomeres had a significantly adverse outcome (P = 0.015). Chromosomal instability was identified in 65% of tumors, significantly correlating with short telomeres (P = 0.0094). Using multivariate analysis, telomere length remained the only significant prognostic variable (P = 0.034). Patients with short telomeres had a 5.3-fold risk of relapse as compared to those with unchanged or longer telomeres.
CONCLUSION: We have shown that tumors with telomere length reduction result in genomic instability. In addition, telomere length reduction was the only significant predictor of outcome. We suggest that reduction of telomere length in tumor cells at diagnosis could serve as a prognostic marker in Ewing sarcoma.

Entities:  

Mesh:

Year:  2007        PMID: 17908968     DOI: 10.1158/1078-0432.CCR-07-0308

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  Alterations of telomere length in human brain tumors.

Authors:  Majid Kheirollahi; Masoud Mehrazin; Naser Kamalian; Parvin Mehdipour
Journal:  Med Oncol       Date:  2010-04-07       Impact factor: 3.064

2.  Expression of various protection of telomeres 1 variants is associated with telomere length and radiosensitivity in colon and gastric adenocarcinoma cells in vitro.

Authors:  Han Lei; Fu-Xiang Zhou; Hui Xu; Xiao-Hong Peng; Zhi-Guo Zhang; Wen-Bo Wang; Hai-Jun Yu; Cong-Hua Xie; Yun-Feng Zhou
Journal:  Biomed Rep       Date:  2015-03-20

3.  miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells.

Authors:  Ke Jin; Yonghua Xiang; Jing Tang; Guangchun Wu; Junwei Li; Huaichun Xiao; Chunwang Li; Yuxiang Chen; Jingfeng Zhao
Journal:  Tumour Biol       Date:  2014-02

4.  Correlations of telomere length, P53 mutation, and chromosomal translocation in soft tissue sarcomas.

Authors:  Chunxia Liu; Bingcheng Li; Li Li; Haijun Zhang; Yunzhao Chen; Xiaobin Cui; Jianming Hu; Jingfang Jiang; Yan Qi; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  A prospective study of telomere length and the risk of skin cancer.

Authors:  Jiali Han; Abrar A Qureshi; Jennifer Prescott; Qun Guo; Li Ye; David J Hunter; Immaculata De Vivo
Journal:  J Invest Dermatol       Date:  2008-07-31       Impact factor: 8.551

6.  Are short telomeres hallmarks of cancer recurrence?

Authors:  Jerry W Shay
Journal:  Clin Cancer Res       Date:  2013-12-23       Impact factor: 12.531

Review 7.  Association between telomere length and survival in cancer patients: a meta-analysis and review of literature.

Authors:  Xinsen Xu; Kai Qu; Qing Pang; Zhixin Wang; Yanyan Zhou; Chang Liu
Journal:  Front Med       Date:  2016-05-16       Impact factor: 4.592

Review 8.  Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.

Authors:  Cormac Owens; Lesleigh S Abbott; Abha A Gupta
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

9.  Dynamic length changes of telomeres and their nuclear organization in chronic myeloid leukemia.

Authors:  Oumar Samassekou
Journal:  Cancers (Basel)       Date:  2013-08-22       Impact factor: 6.639

10.  The clinical use of biomarkers as prognostic factors in Ewing sarcoma.

Authors:  Annmeik M van Maldegem; Pancras Cw Hogendoorn; Andrew B Hassan
Journal:  Clin Sarcoma Res       Date:  2012-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.